AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30826774 — intervention group
Group type: EXPERIMENTAL
Intervention: ianalumab 10 mg/kg
Number of subjects: 27
Study 30826774 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study 28211603 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month dual antiplatelet therapy (DAPT)
Number of subjects: 2737
Study 28211603 — intervention group
Group type: COMPARATOR
Intervention: 6-month dual antiplatelet therapy (DAPT)
Number of subjects: 2737
Study 28211603 — intervention group
Group type: COMPARATOR
Intervention: 6-month DAPT
Number of subjects: 2737
Study 28211603 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month DAPT
Number of subjects: 2737
Study 26100253 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) combined with standard chemotherapy
Number of subjects: 1453
Study 26100253 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1453
Study 24094982 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative low dose vaginal oestrogens
Number of subjects: 0
Study 24094982 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 21484217 — intervention group
Group type: EXPERIMENTAL
Intervention: Envelope flap
Number of subjects: 20
Study 21484217 — intervention group
Group type: COMPARATOR
Intervention: Triangular flap
Number of subjects: 20
Study 19847908 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1,000 mg intravenous infusions every 24 weeks for 96 weeks)
Number of subjects: 439
Study 19847908 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 439
Study 19847908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study 17715724 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient estimates of overall costs of total knee arthroplasty
Number of subjects: 39
Study 17715724 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient estimates of surgeon's fee
Number of subjects: 39
Study 15555386 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting and transferring system for tuberculosis patients in general hospitals and township clinics
Number of subjects: 0
Study 15555386 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 11487673 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA with Palmaz stent placement
Number of subjects: 53
Study 11487673 — intervention group
Group type: COMPARATOR
Intervention: PTA alone
Number of subjects: 53
Study 9771949 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (600 mg/day for 5 days)
Number of subjects: 11
Study 9771949 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (60 mg/m2) without toremifene
Number of subjects: 11
Study 7828688 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine administered via a handheld DeVilbiss nebulizer
Number of subjects: 48
Study 7828688 — intervention group
Group type: COMPARATOR
Intervention: Methacholine administered via a dosimeter
Number of subjects: 48
Study 7828688 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen droplet method
Number of subjects: 48
Study 7828688 — intervention group
Group type: COMPARATOR
Intervention: Phazet
Number of subjects: 48
Study 3276283 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine treatment
Number of subjects: 9
Study 3276283 — intervention group
Group type: EXPERIMENTAL
Intervention: mCPP administration after clomipramine treatment
Number of subjects: 9
Study 3276283 — intervention group
Group type: COMPARATOR
Intervention: mCPP administration before clomipramine treatment
Number of subjects: 9
Study 31801395 — intervention group
Group type: EXPERIMENTAL
Intervention: LBEC0101 (etanercept biosimilar)
Number of subjects: 0
Study 31801395 — intervention group
Group type: COMPARATOR
Intervention: ETN-RP (etanercept reference product)
Number of subjects: 0
Study 31801395 — intervention group
Group type: EXPERIMENTAL
Intervention: LBEC0101
Number of subjects: 0
Study 31801395 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN-RP to LBEC0101 switch
Number of subjects: 0
Study 31801395 — intervention group
Group type: COMPARATOR
Intervention: ETN-RP
Number of subjects: 0
Study 31986074 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning
Number of subjects: 0
Study 30671976 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (1440 mg/day) for 6 months
Number of subjects: 97
Study 30671976 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 97
Study 27780368 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 0
Study 27780368 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study 25867123 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rLSMS
Number of subjects: 26
Study 25867123 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz repetitive TMS
Number of subjects: 26
Study 25867123 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 26
Study 23288387 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium plus optimized personalized treatment (OPT)
Number of subjects: 283
Study 23288387 — intervention group
Group type: COMPARATOR
Intervention: Optimized personalized treatment (OPT) alone
Number of subjects: 283
Study 21617168 — intervention group
Group type: EXPERIMENTAL
Intervention: A1AT replacement therapy
Number of subjects: 102
Study 21617168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 18957157 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 132
Study 18957157 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline
Number of subjects: 132
Study 18957157 — intervention group
Group type: COMPARATOR
Intervention: Control group (no saline treatment)
Number of subjects: 132
Study 16943174 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) - 10 sessions
Number of subjects: 143
Study 16943174 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CAU)
Number of subjects: 143
Study 15116987 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous shifts of attention measured using a probe reaction time task
Number of subjects: 0
Study 15116987 — intervention group
Group type: COMPARATOR
Intervention: Visual search tasks
Number of subjects: 0
Study 10830767 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% clindamycin vaginal cream
Number of subjects: 1102
Study 10830767 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 1102
Study 8980952 — intervention group
Group type: EXPERIMENTAL
Intervention: Method A (previous method of sputum induction)
Number of subjects: 11
Study 8980952 — intervention group
Group type: COMPARATOR
Intervention: Method B (separate collection of saliva and sputum)
Number of subjects: 11
Study 8980952 — intervention group
Group type: EXPERIMENTAL
Intervention: Method A
Number of subjects: 11
Study 8980952 — intervention group
Group type: COMPARATOR
Intervention: Method B
Number of subjects: 11
Study 1641117 — intervention group
Group type: EXPERIMENTAL
Intervention: Well structured fragmented forms
Number of subjects: 2
Study 1641117 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorly structured forms
Number of subjects: 2
Study 1641117 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetrical stimuli
Number of subjects: 2
Study 1641117 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique condition
Number of subjects: 2
Study 1641117 — intervention group
Group type: COMPARATOR
Intervention: Well structured forms
Number of subjects: 2
Study 6562083 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive patient education group
Number of subjects: 36
Study 6562083 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 30317336 — intervention group
Group type: EXPERIMENTAL
Intervention: Single visit endodontic treatment (Group-I)
Number of subjects: 60
Study 30317336 — intervention group
Group type: COMPARATOR
Intervention: Multiple visit endodontic treatment (Group-II)
Number of subjects: 60
Study 28615379 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS-PL) containing 250 μg I, 20 g/d, 118 kcal
Number of subjects: 4011
Study 28615379 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid (IFA; 60 mg Fe/d + 400 μg folic acid/d)
Number of subjects: 4011
Study 24390403 — intervention group
Group type: EXPERIMENTAL
Intervention: KiVa antibullying program
Number of subjects: 7491
Study 21810005 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg once daily (dose‐increase group)
Number of subjects: 51
Study 21810005 — intervention group
Group type: COMPARATOR
Intervention: Olopatadine 5 mg twice daily (drug‐change group)
Number of subjects: 51
Study 21810005 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine 10 mg once daily (initial treatment)
Number of subjects: 51
Study 21810005 — intervention group
Group type: EXPERIMENTAL
Intervention: Skindex‐16 (Quality of Life assessment)
Number of subjects: 51
Study 21118744 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of venlafaxine extended-release 75-mg capsules (fasting)
Number of subjects: 48
Study 21118744 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of venlafaxine extended-release 75-mg capsules (fasting)
Number of subjects: 48
Study 21118744 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of venlafaxine extended-release 75-mg capsules (fed)
Number of subjects: 48
Study 21118744 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of venlafaxine extended-release 75-mg capsules (fed)
Number of subjects: 48
Study 21118744 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (fasting and fed)
Number of subjects: 48
Study 21118744 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (both phases)
Number of subjects: 48
Study 18946626 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate 25 mg IM every 2 weeks
Number of subjects: 188
Study 18946626 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate 12.5 mg IM every 4 weeks
Number of subjects: 188
Study 18946626 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate 25 mg IM every 4 weeks
Number of subjects: 188
Study 18946626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 18946626 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate (all doses)
Number of subjects: 188
Study 15908335 — intervention group
Group type: EXPERIMENTAL
Intervention: Stilamin 250 microg/h
Number of subjects: 20
Study 15908335 — intervention group
Group type: EXPERIMENTAL
Intervention: Stilamin 500 microg/h
Number of subjects: 20
Study 15908335 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandostatin 100 microg
Number of subjects: 20
Study 12839518 — intervention group
Group type: EXPERIMENTAL
Intervention: GHQ‐12
Number of subjects: 1808
Study 10410404 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric tetracaine (2.0 mL of 0.5% tetracaine in 5% dextrose)
Number of subjects: 60
Study 10410404 — intervention group
Group type: COMPARATOR
Intervention: Isobaric tetracaine (2.0 mL of 0.5% tetracaine in cerebrospinal fluid)
Number of subjects: 60
Study 7552876 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia during routine dental extractions
Number of subjects: 39
Study 2188926 — intervention group
Group type: EXPERIMENTAL
Intervention: aclacinomycin-A (ACM-A, 100 mg/m2 or 85 mg/m2, every 3 weeks)
Number of subjects: 98
Study 2188926 — intervention group
Group type: COMPARATOR
Intervention: 6-diazo-5-oxo-L-norleucine (DON; 50 mg/m2/day for 5 consecutive days every 4 weeks)
Number of subjects: 98
Study 7386656 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (Tegretol) 600-1600 mg/day
Number of subjects: 22
Study 7386656 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (Tegretol)
Number of subjects: 22
Study 7386656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30868176 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 187
Study 30868176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 27980028 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal home visiting model employing a nurse-parent educator team
Number of subjects: 244
Study 27980028 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 244
Study 26042920 — intervention group
Group type: EXPERIMENTAL
Intervention: Large plate (12-inch)
Number of subjects: 137
Study 26042920 — intervention group
Group type: COMPARATOR
Intervention: Small plate (8-inch)
Number of subjects: 137
Study 26042920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive eating levels
Number of subjects: 137
Study 23377392 — intervention group
Group type: EXPERIMENTAL
Intervention: Efinaconazole 10% solution (with or without semiocclusion)
Number of subjects: 135
Study 23377392 — intervention group
Group type: EXPERIMENTAL
Intervention: Efinaconazole 5% solution
Number of subjects: 135
Study 23377392 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 135
Study 21113661 — intervention group
Group type: EXPERIMENTAL
Intervention: WALC‐S (motivational intervention)
Number of subjects: 97
Study 21113661 — intervention group
Group type: COMPARATOR
Intervention: TAC (time and attention control group)
Number of subjects: 97
Study 19534587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tanshinone IIA sulfonate (STS) 60 mg day(-1) injections for 13 days
Number of subjects: 16
Study 19534587 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections for 13 days
Number of subjects: 16
Study 17332003 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 17332003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15375791 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight subjects
Number of subjects: 62
Study 15375791 — intervention group
Group type: COMPARATOR
Intervention: Normal weight subjects
Number of subjects: 62
Study 15375791 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin levels
Number of subjects: 62
Study 15375791 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 62
Study 15375791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of adiponectin and %BF
Number of subjects: 62
Study 15375791 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of adiponectin with insulin sensitivity
Number of subjects: 62
Study 15375791 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin and hs‐CRP levels
Number of subjects: 62
Study 11252522 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 0
Study 9726499 — intervention group
Group type: EXPERIMENTAL
Intervention: Self instructional CD‐ROM tutorial program
Number of subjects: 27
Study 9726499 — intervention group
Group type: COMPARATOR
Intervention: Conventional classroom demonstration
Number of subjects: 27
Study 9726499 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both methods
Number of subjects: 27
Study 9505987 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg venlafaxine tablet
Number of subjects: 0
Study 9505987 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg venlafaxine tablet with food
Number of subjects: 0
Study 9505987 — intervention group
Group type: COMPARATOR
Intervention: 50 mg venlafaxine solution
Number of subjects: 0
Study 2036242 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy (total nodal or involved field irradiation)
Number of subjects: 118
Study 2036242 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 118
Study 6260873 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin
Number of subjects: 38
Study 6260873 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytohemagglutinin
Number of subjects: 38
Study 6260873 — intervention group
Group type: COMPARATOR
Intervention: Seropositive controls
Number of subjects: 38
Study 6260873 — intervention group
Group type: COMPARATOR
Intervention: Seronegative controls
Number of subjects: 38
Study 30088663 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-246475 1 mg
Number of subjects: 48
Study 30088663 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-246475 2 mg
Number of subjects: 48
Study 30088663 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-246475 4 mg
Number of subjects: 48
Study 30088663 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-246475 8 mg
Number of subjects: 48
Study 30088663 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-246475 16 mg
Number of subjects: 48
Study 30088663 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-246475 32 mg
Number of subjects: 48
Study 30088663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 28854980 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial stress
Number of subjects: 1047
Study 28854980 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking-induced deprivation
Number of subjects: 1047
Study 28854980 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial stress and deprivation association
Number of subjects: 1047
Study 28854980 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation to quit
Number of subjects: 1047
Study 26363128 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI-free immunosuppression with everolimus and mycophenolic acid
Number of subjects: 200
Study 26363128 — intervention group
Group type: COMPARATOR
Intervention: Reduced-exposure CNI with concomitant everolimus
Number of subjects: 200
Study 23477375 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety guidewire (SGW)
Number of subjects: 40
Study 23477375 — intervention group
Group type: COMPARATOR
Intervention: No safety guidewire (SGW)
Number of subjects: 40
Study 21979114 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + Pulmonary Rehabilitation (PR)
Number of subjects: 60
Study 21979114 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 60
Study 21979114 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 18456226 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 0
Study 18456226 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy
Number of subjects: 0
Study 17158418 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial insulinemic response
Number of subjects: 28
Study 17158418 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial glycemic response
Number of subjects: 28
Study 17158418 — intervention group
Group type: EXPERIMENTAL
Intervention: Low breakfast energy intake (EI)
Number of subjects: 28
Study 12667149 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron cooking pots
Number of subjects: 322
Study 12667149 — intervention group
Group type: COMPARATOR
Intervention: Aluminium cooking pots
Number of subjects: 322
Study 10878651 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation and deworming in the study area
Number of subjects: 458
Study 8907258 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyclonine (40 ml enema)
Number of subjects: 10
Study 8907258 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 1833834 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg twice daily
Number of subjects: 0
Study 1833834 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 5.0 mg twice daily
Number of subjects: 0
Study 1833834 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 mg twice daily
Number of subjects: 0
Study 6126425 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole injections
Number of subjects: 60
Study 6126425 — intervention group
Group type: COMPARATOR
Intervention: PCPL injections
Number of subjects: 60
Study 31973094 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF-ATSS condition
Number of subjects: 70
Study 31973094 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF-Only condition
Number of subjects: 70
Study 31973094 — intervention group
Group type: COMPARATOR
Intervention: Control+ATSS condition
Number of subjects: 70
Study 30762754 — intervention group
Group type: EXPERIMENTAL
Intervention: SPT and SMV (SPT-SMV)
Number of subjects: 37
Study 30762754 — intervention group
Group type: COMPARATOR
Intervention: SPT
Number of subjects: 37
Study 26519049 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 148
Study 26519049 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 148
Study 26519049 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 148
Study 25656161 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training (n-back training)
Number of subjects: 0
Study 24928479 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200mg/day)
Number of subjects: 64
Study 24928479 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20mg/day)
Number of subjects: 64
Study 24928479 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil + Escitalopram (200+20mg/day)
Number of subjects: 64
Study 24928479 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0mg/day)
Number of subjects: 64
Study 22492091 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (10 μg, SC)
Number of subjects: 15
Study 22492091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 19082719 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal endoscopy (TN)
Number of subjects: 200
Study 19082719 — intervention group
Group type: COMPARATOR
Intervention: Transoral endoscopy (TO)
Number of subjects: 200
Study 17766093 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (1500 mg/day)
Number of subjects: 30
Study 17766093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15138674 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory physiotherapy
Number of subjects: 81
Study 15138674 — intervention group
Group type: COMPARATOR
Intervention: Suction
Number of subjects: 81
Study 11775405 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 9853771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 32
Study 9853771 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine
Number of subjects: 32